Basit öğe kaydını göster

Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.

dc.contributor.authorAYDINER, Adnan
dc.contributor.authorTAS, Faruk
dc.contributor.authorTOPUZ, E
dc.contributor.authorCAMLICA, Hakan
dc.contributor.authorYasasever, V
dc.contributor.authorUSTUNER, Z
dc.contributor.authorDURANYILDIZ, D
dc.date.accessioned2021-03-03T13:22:18Z
dc.date.available2021-03-03T13:22:18Z
dc.date.issued2004
dc.identifier.citationTAS F., Yasasever V., DURANYILDIZ D., CAMLICA H., USTUNER Z., AYDINER A., TOPUZ E., "Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.", American journal of clinical oncology, cilt.27, sa.3, ss.225-8, 2004
dc.identifier.issn0277-3732
dc.identifier.otherav_33a6379d-9b0f-425a-899e-21a4e6c08e77
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/38962
dc.identifier.urihttps://doi.org/10.1097/01.coc.0000054895.39558.db
dc.description.abstractSerum protein S100 and melanoma-inhibitory protein (MIA) have been described as useful tumor markers for malignant melanoma. In this study, these two serum proteins were compared in 48 patients with melanoma at different stages of disease. Serum concentrations of S 100 and MIA were measured by immunoradiometric and enzyme-linked immunosorbent assays, respectively. We found that the cut-off values were 17.4 ng/ml for MIA and 0.09 mug/l for S100. Five patients had stage I-II, 22 had stage III, and 21 had stage IV disease. Serum levels of two markers were elevated with metastatic disease (p 0.05). We showed a trend for worsened outcome in patients with elevated MIA level in univariate analysis. MIA was found to be more sensitive and is a potential prognostic marker for patients with metastatic malignant melanoma in comparison with S100.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleClinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
dc.typeMakale
dc.relation.journalAmerican journal of clinical oncology
dc.contributor.department, ,
dc.identifier.volume27
dc.identifier.issue3
dc.identifier.startpage225
dc.identifier.endpage8
dc.contributor.firstauthorID7449


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster